Comparing the efficacy of aprepitant and ondansetron for the prevention of postoperative nausea and vomiting (PONV): A double blinded, randomised control trial in patients undergoing breast and thyroid surgeries
Salome Jeyabalan, Suma Mary Thampi, Reka Karuppusami, Kunder Samuel
Indian Journal of Anaesthesia 2019 63(4):289-294
Background and Aims: Aprepitant, a Neurokinin-1 receptor antagonist, has been evaluated in abdominal and neurosurgeries, but its effect is less clear in breast and thyroid surgeries, which are also known to be high risk for post-operative nausea and vomiting (PONV). This study was done to compare the antiemetic efficacy of ondansetron and aprepitant in women undergoing mastectomy and thyroidectomy. Methods: One hundred and twenty-five ASA I and II, female patients, aged between 18 and 65 years were randomly assigned into Group I (ondansetron group, n = 62) or Group II (aprepitant group, n = 63), by computer-generated random sequencing. Per protocol analysis was done to assess the incidence and severity of PONV, use of rescue antiemetics, and patient satisfaction with PONV control between the two groups, till 24 h post-surgery. Results: In the immediate postoperative period, 79.7% of patients in Group I and 85.2% in Group II were free of emesis (P value: 0.49). In Group I, the first episode of vomiting occurred within a median duration 90 min (IQR 2575: 45-147) postoperatively, whereas the median duration in Group II was 160 min (IQR 25-75: 26-490), with request for rescue antiemetic at 60 min in Group I (IQR 25-75: 27-360) and 147 min in Group II (IQR 25-75: 11-457). Conclusion: A single dose of oral aprepitant has comparable effects to injection ondansetron administered eighth hourly in preventing PONV, the severity of nausea, number of rescue antiemetics, and the time to first emetic episode in the 24-h postoperative period. CTRI Reg No: REF/2017/06/014637.
Salome Jeyabalan, Suma Mary Thampi, Reka Karuppusami, Kunder Samuel
Indian Journal of Anaesthesia 2019 63(4):289-294
Background and Aims: Aprepitant, a Neurokinin-1 receptor antagonist, has been evaluated in abdominal and neurosurgeries, but its effect is less clear in breast and thyroid surgeries, which are also known to be high risk for post-operative nausea and vomiting (PONV). This study was done to compare the antiemetic efficacy of ondansetron and aprepitant in women undergoing mastectomy and thyroidectomy. Methods: One hundred and twenty-five ASA I and II, female patients, aged between 18 and 65 years were randomly assigned into Group I (ondansetron group, n = 62) or Group II (aprepitant group, n = 63), by computer-generated random sequencing. Per protocol analysis was done to assess the incidence and severity of PONV, use of rescue antiemetics, and patient satisfaction with PONV control between the two groups, till 24 h post-surgery. Results: In the immediate postoperative period, 79.7% of patients in Group I and 85.2% in Group II were free of emesis (P value: 0.49). In Group I, the first episode of vomiting occurred within a median duration 90 min (IQR 2575: 45-147) postoperatively, whereas the median duration in Group II was 160 min (IQR 25-75: 26-490), with request for rescue antiemetic at 60 min in Group I (IQR 25-75: 27-360) and 147 min in Group II (IQR 25-75: 11-457). Conclusion: A single dose of oral aprepitant has comparable effects to injection ondansetron administered eighth hourly in preventing PONV, the severity of nausea, number of rescue antiemetics, and the time to first emetic episode in the 24-h postoperative period. CTRI Reg No: REF/2017/06/014637.
I want to share with you all on how Dr Itua saves my life with his powerful Herbal medicines, I was diagnosed of Oral/Ovarian Cancer which i suffered from for 5 years with no positive treatment until when My son came to me in the hospital when i was laying down on my dying bed waiting for god to call out my name to join him in heaven.
ΑπάντησηΔιαγραφήMy son was so excited that very day he came across Dr Itua on Blogspot, we decided to give him a try although we Americans are so scared to trust Africans but i really have no choice that time to choose life in between so we gave a try to Dr Itua Herbal medicines, god wiling he was a good man with a god gift. Dr Itua send us the herbal medicine it was three bottles. I take it for three weeks instructor and this herbal medicines heal me, cure my Oral/Ovarian Cancer completely I have been living for 9 months now with healthy life no more symptoms.
I'm sponsoring Dr Itua in LA Advert on Cancer patent seminar which my son will be participating too and other patent Dr Itua has cured from all kind of human disease, also if you are sick from disease like,Epilepsy,Breast Cancer,Prostate Cancer,Throat cancer,Thyroid Cancer,Uterine cancer,Fibroid,Angiopathy, Ataxia,Arthritis,Brain cancer,Hiv,. Vaginal cancer,Herpes,Colon-Rectal Cancer,Chronic Disease.Amyotrophic Lateral Scoliosis,Brain Tumor,Fibromyalgia,Fluoroquinolone Toxicity,Multiple myeloma,Tach Diseases,Leukemia,Liver cancer,
Esophageal cancer,Gallbladder cancer,,Bladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma
Intestinal cancer,Kidney cancer,Hpv,Lung cancer,Adrenal cancer.Bile duct cancer,Bone cancer,Melanoma,Mesothelioma,Neuroendocrine tumors
Non-Hodgkin lymphoma,Cervical Cancer,Oral cancer,Hepatitis,Skin cancer,Soft tissue sarcoma,Spinal cancer,Pancreatic Cancer, Stomach cancer
Testicular cancer,
Syndrome Fibrodysplasia Ossificans ProgresSclerosis,Alzheimer's disease,Chronic Diarrhea,Copd,Parkinson,Als,Adrenocortical carcinoma Infectious mononucleosis,Vulvar cancer,Ovarian cancer,,Sinus cancer, Here Is The Wonderful Healer Contact. Name_ Doctor Itua, Email Contact: drituaherbalcenter@gmail.com, Phone/WhatsApp: +2348149277967